Yonkenafil
Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease[1].
Product Specifications
CAS Number
804518-63-6
Product Name Alternative
Tunodafil
UNSPSC
12352005
Hazard Statement
H302-H315-H319
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/yonkenafil.html
Purity
99.52
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C2=C(N(CCC)C=C2C)N=C(C3=CC(S(=O)(N4CCN(CC)CC4)=O)=CC=C3OCC)N1
Molecular Formula
C24H33N5O4S
Molecular Weight
487.61
Precautions
P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![7-(3-Bromophenyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile](https://cdn.genprice.uk/products/572/105292945859/imageurl/trc-b686550-250mg.webp)
7-(3-Bromophenyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile
